Trillium Therapeutics Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Trillium Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Trillium Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward indicators, Trillium Therapeutics is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Quick Ratio | 18.70 | |
| Fifty Two Week Low | 5.80 | |
| Target High Price | 14.17 | |
| Fifty Two Week High | 20.96 | |
| Target Low Price | 7.87 |
Trillium |
Trillium Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Trillium Therapeutics on January 30, 2024 and sell it today you would earn a total of 100.00 from holding Trillium Therapeutics or generate -100.0% return on investment over 90 days. Trillium Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Trillium, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trillium Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trillium Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trillium Therapeutics, and traders can use it to determine the average amount a Trillium Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TRIL |
Based on monthly moving average Trillium Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trillium Therapeutics by adding Trillium Therapeutics to a well-diversified portfolio.
Trillium Therapeutics Fundamentals Growth
Trillium Stock prices reflect investors' perceptions of the future prospects and financial health of Trillium Therapeutics, and Trillium Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trillium Stock performance.
| Return On Equity | -30.19 | |||
| Return On Asset | -16.38 | |||
| Current Valuation | 741.27 M | |||
| Shares Outstanding | 103.14 M | |||
| Price To Earning | (1.89) X | |||
| Price To Book | 7.38 X | |||
| Revenue | 148 K | |||
| EBITDA | (55.62 M) | |||
| Cash And Equivalents | 275.65 M | |||
| Cash Per Share | 2.67 X | |||
| Total Debt | 794 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 2.50 X | |||
| Cash Flow From Operations | (32.52 M) | |||
| Earnings Per Share | (0.57) X | |||
| Total Asset | 64.82 M | |||
| Retained Earnings | (47 M) | |||
| Current Asset | 64.02 M | |||
| Current Liabilities | 2.56 M |
Things to note about Trillium Therapeutics performance evaluation
Checking the ongoing alerts about Trillium Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trillium Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trillium Therapeutics is not yet fully synchronised with the market data | |
| Trillium Therapeutics has some characteristics of a very speculative penny stock | |
| Trillium Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 148 K. Net Loss for the year was (53.91 M) with profit before overhead, payroll, taxes, and interest of 148 K. | |
| Trillium Therapeutics currently holds about 275.65 M in cash with (32.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67. | |
| Over 76.0% of the company shares are owned by institutional investors |
- Analyzing Trillium Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trillium Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Trillium Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trillium Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trillium Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trillium Therapeutics' stock. These opinions can provide insight into Trillium Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Trillium Stock
If you are still planning to invest in Trillium Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Trillium Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |